FPMI Names Edward L. Lyons to Newly Created Position of Vice President, Marketing
News Oct 29, 2013
FluoroPharma Medical, Inc. has announced that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to FluoroPharma's newly created position of Vice President, Marketing.
Mr. Lyons will be responsible for the global development and commercial strategy for FluoroPharma's nuclear cardiology portfolio and will report directly to FluoroPharma's Chairman and CEO, Thijs Spoor.
"We are delighted that Ed Lyons, a distinguished healthcare veteran with vast experience in nuclear cardiology across the health care continuum, from hospital to pharmaceuticals and diagnostics; and with the expertise to develop strategic and operational programs that drive growth, has joined our company at such a defining moment in our evolution. Today's announcement reflects the confidence we have in our vision to enable personalized medicine through precision diagnostics, the strength of our science and the promise of our portfolio. We created this position to manage our global strategies, advance our approach to launching, marketing and selling our products as well as strengthening our potential for strategic partnerships," said Mr. Spoor.
"I am excited to be a member of the FluoroPharma team and look forward to contributing to our success. My career has been devoted to diagnostic imaging, and PET is ideal for the early detection and diagnosis of diseases. I believe that the development of new molecular diagnostic imaging agents will extend the utility of PET, while helping to address the global economic challenges of healthcare delivery. FluoroPharma's diagnostics could provide better information for clinicians that will further enable doctors and patients to make more informed choices on treatment. I believe FluoroPharma's pipeline holds great promise, I am confident we have the tools to make the promise become the reality," said Mr. Lyons.
Prior to joining FluoroPharma, Mr. Lyons was with GE Healthcare where he held management positions of increasing responsibility, culminating in his appointment to Global Marketing Director, Nuclear Medicine, where he was responsible for the worldwide marketing of the general purpose, hybrid imaging and direct-conversion detector camera portfolios.
During his tenure with GE Healthcare, Mr. Lyons successfully launched AdreView ™ and was responsible for the Cardiology commercial and development portfolios. In 2008, the business received the Frost and Sullivan Award for Radiopharmaceutical Marketing Excellence.
Before GE Healthcare, Mr. Lyons was with Bristol-Myers Squibb Medical Imaging, where he held positions in Medical Affairs Field Operations and Marketing. Prior to Bristol-Myers, Mr. Lyons was with DuPont Pharmaceuticals, where over the span of ten years he held positions in Nuclear Cardiology ranging from Sales and Marketing to Medical Affairs, where he was appointed to Director.
Mr. Lyons began his career within the hospital environment, where he was Chief Technologist in Nuclear Medicine and Nuclear Cardiology at Philadelphia Heart Institute, and Temple University Hospital.
Throughout his career, Mr. Lyons has contributed to numerous publications and white papers, and has presented on a variety of medical imaging topics at prestigious industry conferences and meetings.
Mr. Lyons has a diverse educational background in Management Theory and Practice, Marketing Excellence, Strategic Planning and Six Sigma. He holds active board certifications from Temple University School of Nuclear Medicine Technology and Albert Einstein School of Radiologic Technology.
Enterome and Nestlé Health Sciences Launch New Diagnostics CompanyNews
Enterome and Nestlé Health Sciences join to create Microbiome Diagnostics Partners, a company that will enable the development and diagnostics for multiple diseases including inflammatory bowel diseases (IBD) and liver diseases.READ MORE
Material From Shellfish Boosts Sensitivity of Diagnostic TestsNews
By adding polydopamine at a key step, the sensitivity of diagnostic tests and bioassays can be increased by as many as 100 to 1,000 times.READ MORE